X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs TORRENT PHARMA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA TORRENT PHARMA FULFORD INDIA/
TORRENT PHARMA
 
P/E (TTM) x 398.8 35.8 1,114.2% View Chart
P/BV x 6.2 5.6 111.4% View Chart
Dividend Yield % 0.1 1.0 8.7%  

Financials

 FULFORD INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
TORRENT PHARMA
Mar-17
FULFORD INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9421,768 53.3%   
Low Rs4501,186 38.0%   
Sales per share (Unadj.) Rs691.4346.1 199.8%  
Earnings per share (Unadj.) Rs11.555.2 20.8%  
Cash flow per share (Unadj.) Rs15.473.3 21.0%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.30.9 30.3%  
Book value per share (Unadj.) Rs380.0257.1 147.8%  
Shares outstanding (eoy) m3.90169.22 2.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.3 23.6%   
Avg P/E ratio x60.726.8 226.9%  
P/CF ratio (eoy) x45.320.1 225.0%  
Price / Book Value ratio x1.85.7 31.9%  
Dividend payout %17.425.4 68.8%   
Avg Mkt Cap Rs m2,714249,887 1.1%   
No. of employees `0000.411.8 3.8%   
Total wages/salary Rs m5059,934 5.1%   
Avg. sales/employee Rs Th6,073.04,971.5 122.2%   
Avg. wages/employee Rs Th1,137.4843.2 134.9%   
Avg. net profit/employee Rs Th100.7792.4 12.7%   
INCOME DATA
Net Sales Rs m2,69658,569 4.6%  
Other income Rs m1252,233 5.6%   
Total revenues Rs m2,82260,802 4.6%   
Gross profit Rs m-4613,773 -0.3%  
Depreciation Rs m153,069 0.5%   
Interest Rs m102,056 0.5%   
Profit before tax Rs m5410,881 0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m101,545 0.6%   
Profit after tax Rs m459,336 0.5%  
Gross profit margin %-1.723.5 -7.3%  
Effective tax rate %17.714.2 124.5%   
Net profit margin %1.715.9 10.4%  
BALANCE SHEET DATA
Current assets Rs m1,73853,841 3.2%   
Current liabilities Rs m54531,612 1.7%   
Net working cap to sales %44.338.0 116.6%  
Current ratio x3.21.7 187.4%  
Inventory Days Days4897 49.9%  
Debtors Days Days484 5.1%  
Net fixed assets Rs m1242,079 0.0%   
Share capital Rs m39846 4.6%   
"Free" reserves Rs m1,44342,655 3.4%   
Net worth Rs m1,48243,501 3.4%   
Long term debt Rs m022,408 0.0%   
Total assets Rs m2,077101,250 2.1%  
Interest coverage x6.76.3 106.7%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.6 224.5%   
Return on assets %2.611.3 23.2%  
Return on equity %3.021.5 14.1%  
Return on capital %4.319.6 21.9%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1720,066 0.1%   
Fx outflow Rs m6735,304 12.7%   
Net fx Rs m-65614,762 -4.4%   
CASH FLOW
From Operations Rs m9010,127 0.9%  
From Investments Rs m105-7,869 -1.3%  
From Financial Activity Rs m-14-1,918 0.7%  
Net Cashflow Rs m181212 85.3%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 7.0 54.1%  
FIIs % 0.1 12.6 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 8.8 240.9%  
Shareholders   4,783 26,511 18.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 218 Points Lower; Tata Steel & Tata Motors Top Losers(Closing)

Indian share markets ended lower in the final hour of the trade. At the closing bell, the BSE Sensex finished lower by 218 points and the NSE Nifty finished down by 82 points.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)

Jul 3, 2018

Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS